严重烧伤患者多黏菌素B群体药代动力学与给药优化
本研究在53例严重烧伤患者中建立多黏菌素B群体药代动力学模型,分析118个血药浓度,发现血尿素氮与清除率负相关,蒙特卡洛模拟支持MIC≤0.5 mg·L⁻¹时75 mg q12h方案达标率>90%。
要点
- 血尿素氮是影响多黏菌素B清除率的显著协变量。
- MIC≤0.5 mg·L⁻¹时75 mg q12h方案达标率>90%且超治疗暴露风险低。
- 推荐定期监测血尿素氮和治疗药物监测以个体化给药。
核心结论
- 75 mg q12h方案(针对MIC≤0.5 mg·L⁻¹)是严重烧伤患者的有效给药方案。
- 建议定期监测血尿素氮和治疗药物监测以实施个体化给药。
研究设计与样本
- 基于53例严重烧伤患者的118个多黏菌素B血药浓度,使用NONMEM建立群体药代动力学模型。
- 采用蒙特卡洛模拟设计给药方案,目标治疗窗为AUCss,24h 50-100 mg·h·L⁻¹,PK/PD阈值为AUCss,24h/MIC>50,目标 attainment 概率≥90%。
主要发现
- 一室模型加一阶消除可描述数据,血尿素氮与清除率呈负相关。
- 负荷剂量对达标概率或治疗窗内AUCss,24h比例影响极小。
- MIC≤0.5 mg·L⁻¹时,75 mg q12h方案达标率>90%且AUCss,24h>100 mg·h·L⁻¹风险低。
- MIC 1 mg·L⁻¹时,仅中高血尿素氮患者使用100 mg q12h方案达标率≥90%。
关键数值与推荐
- 目标治疗窗:AUCss,24h 50-100 mg·h·L⁻¹。
- PK/PD阈值:AUCss,24h/MIC>50,目标 attainment 概率≥90%。
- MIC≤0.5 mg·L⁻¹时推荐75 mg q12h。
- MIC 1 mg·L⁻¹时,中高血尿素氮患者推荐100 mg q12h。
临床怎么用
- 对严重烧伤患者使用多黏菌素B时,可考虑75 mg q12h方案(MIC≤0.5 mg·L⁻¹)。
- 定期监测血尿素氮和治疗药物监测,以调整剂量实现个体化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Data on polymyxin B (PMB) pharmacokinetics (PK) in patients with severe burns are scarce. We aimed to develop a population PK (PopPK) model for PMB in this population, identify factors influencing PK parameters, and optimise dosing regimens. METHODS: Plasma concentrations were measured using ultra-performance liquid chromatography-tandem mass spectrometry. PopPK modelling was performed with nonlinear mixed-effects modelling (NONMEM). Monte Carlo simulations were used to design PMB regimens targeting an optimal therapeutic window (AUCss,24 h, 50-100 mg·h·L⁻¹) and a PK/pharmacodynamic threshold of AUCss,24 h/MIC > 50, with a ≥ 90 % probability of target attainment (PTA). RESULTS: A total of 118 PMB concentrations from 53 patients were analysed. A one-compartment model with first-order elimination was used to describe the data. Blood urea nitrogen (BUN) was a significant covariate, showing a negative correlation with clearance. Loading doses had a minimal effect on PTA or the proportion of patients achieving an AUCss,24 h within the therapeutic window. At minimum inhibitory concentration (MIC) ≤ 0.5 mg·L⁻¹ , a 75 mg q12h regimen achieved > 90 % PTA with low risk of supratherapeutic exposure (AUCss,24 h > 100 mg·h·L⁻¹). At MIC 1 mg·L⁻¹ , only the 100 mg q12h regimen in patients with moderate-to-high BUN achieved ≥ 90 % PTA. CONCLUSION: Overall, this study provides PK insights into PMB dosing in patients with severe burns, supporting 75 mg q12h (for MIC ≤ 0.5 mg·L⁻¹) as an effective regimen. Regular BUN monitoring and therapeutic drug monitoring are recommended for personalised dosing.
引用
- Yang J, Liu F, Zhao Y, et al. Population pharmacokinetics and dosing optimisation of polymyxin B in patients with severe burns. Burns. 2025. PMID: 41066936. doi:10.1016/j.burns.2025.107696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。